News

IMRT Provides Better QOL in Head and Neck Cancers


 

A HEAD AND NECK CANCER SYMPOSIUM SPONSORED BY THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY

On multivariate analysis accounting for gender, age, radiation intent (definitive vs. postoperative), radiation dose, T stage, primary site, use of concurrent chemotherapy, and neck dissection, the use of IMRT was the only variable independently associated with improved quality of life (P = .01).

Dr. Allen M. Chen

In 1- and 2-year analyses of factors contributing to the difference in UW-QOL score, only "saliva" was found to be significantly different between IMRT and CRT (P less than .001) for both time points. Other examined factors that did not affect the score included pain, appearance, activity, recreation, chewing, swallowing, speech, mood, and anxiety.

"Treatments for dry mouth are fairly primitive and ineffective at present, so preventing dry mouth is so critical. It’s a huge problem. Imagine not being able to make any saliva. And, there are health consequences with respect to things like oral hygiene and dental caries. There’s a cost associated with chronic dry mouth," Dr. Chen said in the interview.

Increased Cost Not That Big

The increase in cost with IMRT isn’t that big, Dr. Bhisham Chera, the principal investigator for the cost study and a radiation oncologist at the University of North Carolina said in an interview.

"On average, it was about $5,000-$6,000 more total," he said. "It is more expensive, but what was shocking to me is that it wasn’t much more expensive as some therapies – like newer chemotherapy drugs, compared to older ones, where there’s a hundred thousand dollar difference in cost and the survival improvement is only a few months."

"We think the incremental increase in cost is justified because of the improvement in dry mouth. If you really compare it to other therapies such as using transperineal prostatectomy vs. robotic prostatectomy or cisplatin vs. cetuximab chemotherapy, the cost difference is vastly greater," he added. "Here, the incremental difference is not that much. It is more expensive, but it’s not astronomically more expensive."

Dr. Sheets, Dr. Chen, and Dr. Chera all stated that they had no disclosures.

Pages

Recommended Reading

Oral HPV Infection More Prevalent in Men Than Women
MDedge Internal Medicine
Cancer Screening Falls Short of Federal Targets
MDedge Internal Medicine
Head/Neck Cancer Treatments Less Effective in HIV Patients
MDedge Internal Medicine
Re-Excision Rates After Breast-Conserving Surgery Vary Greatly
MDedge Internal Medicine
ASCO GU to Spotlight Prostate Cancer Drugs MDV3100 and Radium-223
MDedge Internal Medicine
MDV3100 Cuts Risk of Death in Advanced Prostate Cancer
MDedge Internal Medicine
ALSYMPCA Trial: Radium-223 Prolongs Life in Some Prostate Cancers
MDedge Internal Medicine
Breast Cancer Drug Exemestane Linked to BMD Loss
MDedge Internal Medicine
Breast Cancer Mortality Rises with Age in Older Women
MDedge Internal Medicine
FDA Panel Rejects Denosumab Against Bone Metastasis in Prostate Cancer
MDedge Internal Medicine